Anturol meets overactive bladder endpoint

Antares Pharma Inc. (NYSE-A:AIS) said once-daily topical Anturol met the primary endpoint in a Phase III trial to treat overactive bladder (OAB). Both 56 and 84 mg doses of the advanced transdermal de...